Context: Empagliflozin was found to decrease mortality in patients with type 2 diabetes mellitus (T2DM) and a prior cardiovascular disease (CVD) event.
glucose-lowering medications such as sulfonylureas and dipeptidyl peptidase-4 inhibitors may not be associated with a favorable cardiovascular risk profile (3, 4) .
The findings of the EMPA-REG OUTCOME trial (5), reporting substantial cardiovascular and mortality benefits in patients with T2DM receiving empagliflozin, have received intense attention and scrutiny (6) (7) (8) (9) (10) (11) . In this trial, it was reported that patients with T2DM with high risk for cardiovascular disease (CVD) had significant reductions in the relative risk of cardiovascular mortality (38%), all-cause mortality (32%), and hospital admission for heart failure (35%) when a sodium-glucose cotransporter-2 inhibitor (SGLT2i) was added to their background therapy. Importantly, the magnitude of the effect and the rapid onset of action (within 3 months) instigated an ongoing discussion about the potential underlying cardioprotective mechanism(s). The hemodynamic effect resulting from osmotic diuresis, the subsequent activation of the renin-angiotensin-aldosterone system pathways, and the modification of glucagon concentrations have all been proposed as effectors of the additive cardiovascular benefits (6) (7) (8) (9) (10) . Synergy with renin-angiotensin-aldosterone system blockade medications (10) and a favorable SGLT2i-induced metabolic substrate shift (12) are also interesting theories warranting further investigation. On top of this ongoing discussion, an additional series of clinically relevant questions promptly arise and need to be addressed in a timely fashion.
Firstly, it is important to clarify whether the reported CVD benefits are intrinsic to empagliflozin or should be anticipated with the use of other approved SGLT2is such as dapagliflozin. Such trials are currently ongoing, but their results are not expected soon. Secondly, the relevance of any beneficial CVD effects from an SGLT2i in low-risk patients with T2DM is unknown because only patients with a prior CVD event were included in the EMPA-REG OUTCOME trial. Of note, the same partly applies to younger patients with a relatively short duration of diabetes because published data refer to predominantly older patients with long-standing diabetes (7) . Finally, replicating the beneficial CVD results in a pragmatic setting (i.e., other than a strict randomized controlled trial setting) would certainly add to both the external validity and the generalizability of any cardioprotective effects.
To these ends, we conducted a population-based, retrospective, open-cohort study in which patients with T2DM who were exposed to any dapagliflozin were compared with appropriately matched controls with T2DM who were unexposed to dapagliflozin but were receiving a standard background antidiabetic medication.
Research Design and Methods

Study design
In this population-based, retrospective, open-cohort study, patients with T2DM who were exposed to an SGLT2i were compared with appropriately matched patients with T2DM who were unexposed to an SGLT2i. Age, sex, body mass index (BMI), documented duration of T2DM, and smoking status were used as the matching parameters. Given that the great majority (almost 90%) of the exposed cohort was treated with dapagliflozin, analysis and inferences were restricted to those treated with dapagliflozin and their respective controls to promote homogeneity and thus consolidate the findings.
Source of data
Data were derived from The Health Improvement Network (THIN) database. This is a database of anonymized electronic patient records contributed by general practices using the Vision computer system. It includes records from more than 640 UK general practices (;12 million patients, of whom 3.5 million were actively registered with their practices).
Study cohort
The study period was set from 1 January 2013 (study start) to 1 September 2015 (study end; date of last data collection). All individuals in the cohort were required to be registered at their practice for at least a year before entry into the study. The decision to use a 1-year registration period ensured that these were patients with new (i.e., incident) prescriptions rather than patients continued on a prescription that was initiated in another practice. The practices were also required to have used their computer system (Vision) for at least a year prior to their index date and to have an acceptable mortality recording date (an indicator of practice data quality) prior to their index date, thus ensuring that they were making full use of their system and were not under-recording important outcomes (13) .
Exposure
Any subject administered dapagliflozin at any time during the observation period was identified and recorded first. Individuals were included in the exposed cohort if they (1) were aged 18+ years at the index date, (2) had received a diagnosis of diabetes mellitus any time before their index date, (3) had initiated treatment with dapagliflozin, and (4) had remained at their practice at least 3 months after treatment initiation. This date (i.e., 3 months after dapagliflozin prescription) was assigned as the index date for each exposed patient. An intention-to-treat approach was followed, and exposure was assumed to have remained unchanged during the observation period.
Selection of the unexposed cohort (controls)
After the completion of the exposed cohort, the identification of the unexposed patients (i.e., controls) and the matching procedure were applied; by definition, no "control" was exposed to an SGLT2i. For each exposed patient, up to four unexposed controls were selected. Unexposed patients (i.e., controls) (1) were individually matched to cases by sex, age at index date (to within 1 year), BMI (to within 2 kg/m 2 ), duration of diabetes (to within 2 years), and smoking status; (2) had received a diagnosis of diabetes mellitus any time before their index date; and (3) were (by definition) unexposed to an SGLT2i. No additional matching variables were used to ensure a balanced selection for the unexposed group. The diagnosis of diabetes had to be made naturally any time before the index date for all study participants. To avoid immortal time bias, patients in the unexposed cohort were matched at the index date of their respective exposed patient and were assigned the same index as their respective exposed patient.
Follow-up
Exposed and unexposed patients with T2DM were followed up (i.e., the observation period) from the index date until the first of the following events (i.e., the exit date): patient died; patient left practice; last data collection from practice; or patient was diagnosed with any of the following cardiovascular outcomes: myocardial infarction or ischemic heart disease, stroke or transient ischemic attack (TIA), or heart failure or left ventricular dysfunction. When a cardiovascular event was followed by death, the observation period was calculated according to the outcome under study.
Outcomes
The primary outcome was all-cause mortality (death from any cause during the observation period). A composite end point of CVD outcomes (myocardial infarction and ischemic heart disease, stroke or TIA, and heart failure or left ventricular dysfunction) served as a secondary outcome in an analysis restricted to the low-risk population. The low-risk population was defined as patients with an absence of all CVD outcomes (i.e., myocardial infarction and ischemic heart disease, stroke and TIA, and heart failure) at baseline. CVD end points were used as an outcome only in the low-risk subset of the study population. This decision was made to avoid any bias arising from miscoding between incident and prevalent CVD outcomes. Medication-specific effects were also considered in the analysis. The validity of the definition of the primary outcome in the THIN database has been previously documented (14) .
Diagnosis of diabetes mellitus, myocardial infarction and ischemic heart disease, stroke and TIA, and heart failure (inclusive of codes suggestive of left ventricular dysfunction) was determined by the Read Codes (http://systems.hscic.gov.uk/ data/uktc/readcodes).
Covariates
Potential confounders were used as model covariates (on top of the matching parameters of age, sex, BMI, smoking status, and duration of diabetes) and were selected on the basis of biological plausibility. These covariates were glycated hemoglobin level, renal function (on the basis of estimated glomerular filtration rate), systolic blood pressure level, insulin use, the use of lipid-lowering medications, diagnosis of hypertension at baseline, diagnosis of peripheral vascular disease at baseline, and Townsend deprivation index. The latter is a measure of socioeconomic and material deprivation with five categories, starting from the least to the most deprived, and has been validated in THIN database (15) . When all-cause mortality was the outcome, the Charlson comorbidity index was also used as a model covariate (16) . The index encompasses 22 medical conditions weighted from 1 to 6, with total scores ranging from 0 to 37; it has shown marked predictive power for mortality (17) and has been validated for use in the primary care setting (18) .
Statistical analysis
The cohort covariates and matching characteristics were summarized for those exposed and unexposed to dapagliflozin using appropriate descriptive statistics. Differences between exposed and unexposed groups were investigated using x 2 tests (for categorical variables) and t tests or the Mann-Whitney U test for continuous variables. Missing data (the extent of which was minimal, as shown in the Supplemental Appendix) were handled by multiple imputation techniques (chained equations with predicted mean matching). Incidence rate ratios (IRRs) were calculated using Poisson regression. Both crude and adjusted estimates were presented. The statistical significance level was set at 0.05 (two-sided), and 95% confidence intervals (CIs) were presented. All analyses were performed in Stata/MP 14.0. This study was approved by the relevant scientific review committee (SRC Reference Number: 16THIN032A1).
Sensitivity, subgroup, and supplemental analyses
Although it was reasonable to assume that dapagliflozin was prescribed exclusively to patients with T2DM and that Read Codes specific for type 1 diabetes mellitus (T1DM) were not included, a supplemental effort to avoid the possibility of sample "contamination" with T1DM cases was also made. Therefore, we performed a sensitivity analysis by excluding those patients who fulfilled eligibility criteria at baseline but subsequently had a Read Code suggestive of T1DM.
To detect any source of spurious causal inference, a supplemental analysis was undertaken using the "negative control" methodology as detailed in Lipsitch et al. (19) and was implemented in a similar study design (20) . We used dipeptidyl peptidase-4 inhibitor as the negative control because it has been shown that no significant effect on all-cause mortality should be expected (3), at least in the short term. Finally, a subgroup analysis was undertaken to explore the risk of death from any cause in the high-risk subset of the population.
Results
Cohort characteristics
A total of 22,124 T2DM patients (4444 exposed to dapagliflozin and 17,680 unexposed patients with T2DM) constituted the final study population. The mean age and BMI were 58.4 years and 34.8 kg/m 2 , respectively, whereas the mean duration of diabetes was ;9 years. Approximately one-fifth of the study population (n = 4350) had a previous CVD event (ischemic heart disease, stroke, and/or heart failure). The mean glycated hemoglobin value in the total study population was 7.7% (61.3 mmol/mol). Table 1 summarizes the key study characteristics on the basis of exposure to dapagliflozin.
All-cause mortality
Patients with diabetes who were administered dapagliflozin were significantly less likely to die of any cause compared with matched controls with diabetes under standard treatment (crude IRR: 0.49; 95% CI: 0.33 to 0.72; P = 0.0001; Table 2 ). This finding remained robust after adjusting for key covariates (adjusted IRR
[aIRR]: 0.50; 95% CI: 0.33 to 0.75; P = 0.001; Table 2 and Fig. 1 ).
All-cause mortality in the low-risk population
In the low-risk subset of the study population, patients with diabetes who were administered dapagliflozin were significantly less likely to die of any cause compared with matched controls with diabetes receiving standard treatment (crude IRR: 0.43; 95% CI: 0.25 to 0.74; P = 0.002; Table 2 ). This finding remained unchanged after adjusting for key covariates (aIRR: 0.44; 95% CI: 0.25 to 0.78; P = 0.005; Table 2 ).
Risk of incident cardiovascular event in the low-risk population
In the low-risk subset of the study population, no difference was detected in the risk of incident CVD between patients with diabetes who were administered dapagliflozin and matched controls with diabetes receiving standard treatment (crude IRR: 1.00, 95% CI: 0.70 to 1.42, P = 0.981; aIRR: 0.89, 95% CI: 0.61 to 1.30, P = 0.55; Table 2 ).
Sensitivity, subgroup, and supplemental analyses
Both magnitude and direction of effects remained unchanged in sensitivity analyses excluding a subset of participants with a Read Code suggestive of T1DM (Supplemental Appendix). Crude and adjusted risks of death from any cause in the high-risk subset of the population were similar in effect size with the ones observed in the low-risk subset and are presented in the Supplemental Appendix. The findings of the negative control analysis were supportive of the validity of the study design, and no evidence of systemic bias was detected.
Discussion
In this observational population-based analysis involving 22,124 individuals with T2DM and ;16,500 personyears of follow-up, our data suggest that patients exposed to dapagliflozin were significantly less likely to die of any cause compared with appropriately matched controls receiving standard background antidiabetic medication. These data extend the observations from patients included through the narrowly specified inclusion criteria of the trials to the general diabetic population and show such patients may similarly benefit. Similarly, our data support the contention that treatment with dapagliflozin was associated with a reduced risk of death from any cause even in the low-risk population. In contrast, although the risk of any CVD event showed a similar trend, it was not found to be significantly different between the low-risk exposed cohort and the unexposed cohort.
These results can be interpreted as confirmatory and reassuring because both the direction and the magnitude of the effect observed in the total study population are similar to findings reported in the EMPA-REG OUTCOME trial (5) and in a relevant meta-analysis of randomized controlled trials (21) . Importantly, the favorable findings now relate to dapagliflozin, which may be equally effective not only in patients at high risk for CVD but also in the low-risk population. Both of these end points have significant clinical and research ramifications. Furthermore, establishing whether reduction in mortality with an SGLT2i represents a class effect across all SGLT2is could be a relevant end point. Because all patients included in the analysis were treated with dapagliflozin, we cannot provide evidence of a class effect; however, we do show that the observations extend to dapagliflozin.
The findings of the current study should be considered in light of its limitations. First, this is retrospective evidence, and the possibility of bias inherent in this study design should be noted. Furthermore, the actual number of events was low, which is reflected in the wide 95% CIs. Therefore, the accuracy of the reported effect size may be undermined, and the 95% CIs may provide a more solid basis for interpretation. Furthermore, the observation period (i.e., a median of almost a year) may be short for CVD outcomes to manifest. Collectively, these shortcomings may have resulted in an underpowered analysis, especially with respect to the low-risk population, which showed a lack of significance for all CVDs. However, both number of events and total person-years of followup in the current study were above relevant minimum requirements (22) . A bias may exist because of preferential prescription of an SGLT2i to a specific subgroup of patients with diabetes who had a survival benefit, but it was negated by appropriate matching and controlling (e.g., controlling for renal function). However, we cannot completely rule out prescription by indication bias. In addition, no information on education and income was available at an individual level. Therefore, we used the Townsend score, based on postcode, as a proxy for measure of deprivation. Of note, the Charlson comorbidity index does not include all comorbidities, such as debilitating neurologic conditions (multiple sclerosis) and nonmalignant hematological diseases (anemia); therefore, it may be an imperfect measure of the comorbidity index on mortality. Finally, it was not feasible to explore differences in cardiovascular mortality between groups because adjudication on the specific cause of death was not possible in the current study design. The latter might also be a methodological concern because there is no documentation that risk of death was actually comparable between groups at baseline. On the other hand, any major established risk factors for CVD and death were taken into account in the matching process (age, sex, BMI, disease duration, smoking) and covariate selection (Charlson comorbidity index, glycemic control, hypertension, hyperlipidemia, renal function, baseline peripheral vascular disease, treatment with insulin, and socioeconomic status).
The clinical and research implications of the findings are of great interest. Our data indicate that the benefits from treatment with SGLT2is observed in high-risk diabetic patients are not only reproducible in the general diabetic population but may also be extended to the lowrisk population when dapagliflozin is considered. This observation should be further pursued in a trial setting. If an incremental mortality benefit is confirmed in subsequent studies, treatment with dapagliflozin might then be considered a reasonable option for a broad range of patients with T2DM.
In conclusion, our findings suggest that dapagliflozin may be associated with a decrease in all-cause mortality irrespective of baseline CVD status.
